Covid-19: two drugs against Sars-CoV-2 were designed and synthesized by the Wenhao Dai team, of the Chinese Academy of Sciences.
Sars-CoV-2 is the etiological agent responsible for the global COVID-19 outbreak.
The main protease (Mpro) of Sars-CoV-2 is a key enzyme that plays a pivotal role in mediating viral replication and transcription.
Scientists designed and synthesized two lead compounds (11a and 11b) targeting Mpro.
Both exhibited excellent inhibitory activity and potent anti-Sars-CoV-2 infection activity.
Both compounds showed good PK properties in vivo, and 11a also exhibited low toxicity, suggesting that these compounds are promising drug candidates.
Trial drug can significantly block early stages of COVID-19 in engineered human tissues (2020-04-10)
COVID-19, antimalarial drugs, malaria and blood type (2020-04-04)
Hydroxychloroquine and azithromycin as a treatment of COVID-19 (2020-03-18)
For more information
The link to the original article:
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
This post is also available in: Italian